Aifang Li

机构：Pfizer (United States), Project Oceanology, First Affiliated Hospital of Henan University, Xi'an Chest Hospital

发表论文 60 篇 · 总被引 1516 次 · h-index 18

代表论文

• CRISPR/Cas9-induced β-carotene hydroxylase mutation in Dunaliella salina CCAP19/18 (2021 · AMB Express · 被引 63)
• A potential paradigm in CRISPR/Cas systems delivery: at the crossroad of microalgal gene editing and algal-mediated nanoparticles (2023 · Journal of Nanobiotechnology · 被引 49)
• Liquiritin targeting Th17 cells differentiation and abnormal proliferation of keratinocytes alleviates psoriasis via NF‐κB and AP ‐1 pathway (2023 · Phytotherapy Research · 被引 37)
• Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles (2023 · Journal of Nanobiotechnology · 被引 34)
• Strategies for High-Efficiency Mutation Using the CRISPR/Cas System (2022 · Frontiers in Cell and Developmental Biology · 被引 34)
• CRISPR/Cas technology promotes the various application of Dunaliella salina system (2020 · Applied Microbiology and Biotechnology · 被引 34)